Ok the market really needs to wake up to what is unfolding here...
Nice presentation!
This is the ONLY in home therapy for ASD sufferers in the world. Parents will certainly buy this product for their children because it works. The device relaxes the minds of children which in turn gives them the opportunity to score more in the 'normal range'. This improves their life. When word gets around about this groundbreaking device mums and dads will want to give this a go for their kids.
Ok so IMO I think some things require updating in the presentation. Perhaps management are just trying to keep it conservative:
According to some reports I've read people with ASD within the population could be as high as 2% rather than 1%..
The target market is around 140,000 kids within the next 24 months - this could potentially be doubled!
Also I noticed they haven't included Australia within their estimated target market, yet Mentee is currently selling in Australia. @ 1% that's a further 240,000 ÷ 2 (to compensate for the targeted age group) = a further 120,000 within the target market. Therefore the updated figure should be more like 260,000. What the hell that's nearly double. That adds a huge amount of extra revenue potential..
Also I'm not sure why they keep harping on about only the 3 to 12 year target segment. There was one 17 year old in the recent study conducted over in the US and it worked perfectly well on him. IMO even though it hasn't properly been tested on adults yet I believe many adults who are in the autism spectrum scale will also purchase one of these devices to see if it works on them. I believe it will... What about other things such as depression? I remember reading a study that kids and adults suffering from autism have a much higher likelihood of developing depression. So therefore depression can also be managed.
As you can see above management are seeking to penetrate 140k consumer market over the next 24 months. Include Australia and this will be doubled and this is just at one percent. There is a high chance within that 24 months timeline that we will also sign other distribution agreements in other parts of the EU.
The product sells for a retail value of (highlighted within the Red Square):
That's $2,895.50 when converted into Australian dollars (with the tablet).
$438.15 per unit to manufacture.
The distributors get a cut from this as well.
The remaining profit is determined from the deals struck with each distribution partner. NTI will profit around 1,200 to $1, 500 per unit.
TARGET MARKET OVER THE NEXT 24 MONTHS INCLUDING AUSTRALIA IN TERMS OF DOLLARS = $1,200 X $260,000 = $312 million excluding ongoing monthly fees. Now we are talking my kind of language!
PS - check out these figures in Aspects latest annual report:
https://www.autismspectrum.org.au/school/aspect-schools
Aspect have over 9 autism specific schools with over 1100 pupils across Australia. If NTI want to make an impact within the target market than this area will be huge, they have big contacts and great support networks!
Just WOW! What an amazing community, what an amazing Australia!
Cheers
Red bar
- Forums
- ASX - By Stock
- NTI
- Ann: Investor Presentation
Ann: Investor Presentation, page-2
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NTI (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.6¢ |
Change
-0.003(4.35%) |
Mkt cap ! $64.55M |
Open | High | Low | Value | Volume |
6.9¢ | 6.9¢ | 6.6¢ | $73.27K | 1.107M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7106 | 6.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.7¢ | 269492 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 589299 | 0.070 |
1 | 36231 | 0.069 |
5 | 240000 | 0.068 |
2 | 255000 | 0.067 |
3 | 262000 | 0.066 |
Price($) | Vol. | No. |
---|---|---|
0.072 | 100000 | 1 |
0.074 | 40000 | 1 |
0.075 | 738582 | 2 |
0.076 | 90000 | 1 |
0.077 | 190000 | 3 |
Last trade - 15.03pm 25/11/2024 (20 minute delay) ? |
Featured News
NTI (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online